Image

Identification of Anti-HIF 1alpha Autoantibodies in Patients With Anorexia Nervosa and Characterization of Their Pathogenic Potential in Undernutrition-associated Hepatic Cytolysis

Identification of Anti-HIF 1alpha Autoantibodies in Patients With Anorexia Nervosa and Characterization of Their Pathogenic Potential in Undernutrition-associated Hepatic Cytolysis

Recruiting
6-65 years
All
Phase N/A

Powered by AI

Overview

Anorexia nervosa (AN) is a psychiatric disorder belonging to the eating disorders (EDs). It is internationally recognized as a priority for improving health care. Among the markers of severity of undernutrition is hepatic cytolysis. Around 30-50% of patients with AN present with hepatic cytolysis, of variable intensity, and usually associated with severe undernutrition. In a previous study, we demonstrated the presence of autoantibodies against HIF1alpha (Hypoxic inducible Factor 1 alpha) in 22% of cases in a sample of patients with AN. HIF1alpha (HIF1a) is a major transcription factor involved in the regulation of satiety and hunger. These autoantibodies were positive in 80% of AN patients with hepatic cytolysis. Taken together, these data led us to hypothesize an anti-HIF1a autoimmune mechanism in AN, potentially involved in the patients' hepatic cytolysis.

This pioneering study, demonstrating the existence of anti-HIF1a autoantibodies, was carried out on a population of 18 patients with AN. To extend investigator's hypothesis, these results need to be confirmed on a larger number of patients, thus increasing the number of patients with AN and hepatic cytolysis. To determine the relevance of these autoantibodies in AN, "healthy" subjects and patients without AN but with hepatic cytolysis should be tested in parallel. Finally, the in vitro pathogenic potential of autoantibodies can be confirmed on a larger scale and studied in greater detail.

The main aim of our study is to evaluate the association between the presence of anti-HIF1a autoantibodies (AAHIF) and that of hepatic cytolysis in patients with anorexia nervosa and undernutrition.

This study is a prospective, cross-sectional, descriptive, multicenter, 2-arm study.

250 patients will be included. Experimental group (n=100)

  • Patients with anorexia nervosa and undernutrition with hepatic cytolysis (CH) (n=70)
  • Patients with anorexia nervosa and undernutrition without hepatic cytolysis (n=30) Comparator control groups (n=150)
  • Control patients under 18 years of age, treated at the CHU de la Timone for scheduled non-inflammatory surgery (orthopedic, ENT, etc.) (n=50): Minor patients
  • Patients (children and adults) with hepatic cytolysis without anorexia nervosa (n=50): Patients without AN with CH
  • Samples from French blood donation establishment: control group consisting of biological blood samples from healthy individuals from the Etablissement Français du Sang (n=50)

Eligibility

Inclusion Criteria:

Experimental group:

  • Male or female, 6 to 65 years of age
  • Anorexia nervosa diagnosed according to DSM-5 criteria
  • Presence of undernutrition according to HAS 2019 criteria
  • Patient having received information about the study and having signed an informed consent form
  • Beneficiary or beneficiary of a social security scheme

Control group:

  • Minor patients :
    • Male or female strictly under 18 years of age
    • Patients undergoing scheduled non-inflammatory surgery (orthopedic, ENT, etc.)
    • Patients who have been informed about the study and have signed an informed consent form.
    • Patients who are beneficiaries or entitled beneficiaries of a social security scheme.
  • Patients without anorexia with livers cytolysis :
    • Male or female between 18 and 65 years of age
    • With hepatic cytolysis determined by an ALT value at least equal to twice the normal value
    • Patient having received information about the study and having signed an informed consent form
    • Patient who is a beneficiary or eligible beneficiary of a social security scheme.
  • samples Etablissement Français de don de sang: no specific criteria

Exclusion Criteria:

  • Patient in a period of exclusion from another research protocol at the time consent is signed.
  • Opposition of patient and parents or legal guardians
  • Psychiatric disorder preventing patient consent to study
  • Person unable to understand the French language
  • Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women).

Study details
    Hepatic Cytolysis

NCT06869590

Assistance Publique Hopitaux De Marseille

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.